Steris PLC stock falls 1.10 percent and underperforms competitors in weak market

9 articles · Updated · MarketWatch · Apr 28

Steris PLC shares closed at $219.75 on Tuesday, lagging rivals as the S&P 500 dropped 0.49% and Dow Jones 0.05%.
The stock remains 18.44% below its 52-week high of $269.44 set on January 16, 2026, with trading volume at 492,096—well below its 50-day average.
While Thermo Fisher rose and Danaher and Becton Dickinson also declined, Steris PLC's underperformance highlights market volatility and sector-specific pressures during this broad downturn.

With strong earnings, why are Steris insiders selling millions in stock as the share price falls?

Can Steris's restructuring outpace industry headwinds like tariffs and new FDA regulations?

Amid a major medtech M&A boom, is Steris positioned to be a buyer or a target?

How will evolving AI regulations in the US and EU impact Steris's product innovation pipeline?

What does the high volume of insider sales signal about the company's long-term growth prospects?